News | October 01, 2009

Positive Outcomes Reported With Supralimus Sirolimus-Eluting Stent With Biodegradable Polymer

Supralimus Sirolimus-Eluting Stent

October 1, 2009 – The six-month clinical outcome of Sahajanand Medical Technologies Supralimus Sirolimus-Eluting Stent with a bioabsorbable polymer was highlighted by the company at TCT 2009. The results were released at EuroPCR 2009 earlier this year and demonstrated excellent results in high risk patients with complex coronary lesions, including high procedural success rate (greater than 97 percent), and sustained safety.

Dr. Ricardo A. Costa, of the Cardiovascular Research Center, Brazil, offered preliminary clinical results at six months from the Multicenter E-Series Registry. He said the stent demonstrated clinical effectiveness of Supralimus in preventing revascularization, with only 2 percent target vessel revascularization (TVR) rate. There were no thrombosis events and no TVR/TLR in the Supralimus treated patient’s in-hospital. The stent thrombosis rate (definite/probable, ARC) up to six months was less than 1 percent.

Out-of Hospital adverse events (N=718) included 2 percent cardiac death, 0.5 percent myocardial infarction (MI) and 4.5 percent of major adverse cardiac event (MACE). Thus the preliminary data with the Supralimus Sirolimus-Eluting Stent has shown promising results, Dr. Costa said.

The study was conducted by Dr. Alexandre Abizaid, Dr. Costa and others from Jan 2007, which involved 1,181 patients with 1,260 lesions and prospectively enrolled in 50 cities of Brazil, Venezuela and India. The included patients were real world scenario with routine or emergency PCI. Mean age of patients was 64 years and risk factors included 79 percent hypertension, 38 percent diabetes, 31 percent smoker, 23 percent with previous MI, 64 percent with dyslipidemia, 34 percent with previous PCI and 46 percent with family history of CAD.

For more information: www.smtpl.com

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now